Our data clearly demonstrate that the treatment of MOLM-13 cells with the class IIA HDAC inhibitor TMP269 downregulates RPs which are overexpressed at the transcriptional level in AML patients. This evidence concerns the gene HDAC9 and acute myeloid leukemia.